This outcome may be attributed to the ERBB4 mutation, as ERBB family mutations have been associated with poor response to PD-1 inhibitors in NSCLC,33 although the underlying mechanism remains undisclosed. Here, ERBB4 is linked to non-small cell lung carcinoma.